Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Sarcoma × nilotinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 4 Leukemia, Myeloid, Chronic-Phase 3 Philadelphia Chromosome 2 Neoplasm Metastasis 2 Substance Withdrawal Syndrome 1 Sarcoma 1 Peritoneal Neoplasms 1 Ovarian Neoplasms 1 Neoplasm, Residual 1 Necrosis 1 Myeloproliferative Disorders 1 Leukemia 1 Genital Neoplasms, Female 1 Colorectal Neoplasms 1 Appendiceal Neoplasms 1

Interventions

Nivolumab 10 pembrolizumab 9 Radiotherapy 9 Magnetic Resonance Spectroscopy 9 Specimen Handling 8 Doxorubicin 8 Cyclophosphamide 7 Biopsy 7 X-Rays 6 Ipilimumab 6 Phantoms, Imaging 5 talimogene laherparepvec 4 Radiation 4 Nuclear Medicine Department, Hospital 4 selpercatinib 3 pazopanib 3 palbociclib 3 cabozantinib 3 Standard of Care 3 Sirolimus 3 Ifosfamide 3 Bevacizumab 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 olaparib 2 liposomal doxorubicin 2 larotrectinib 2 ivosidenib 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡